This Week in Endocrinology — Aug 11, 2026

Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning the expanding cardio-kidney-metabolic reach of incretin therapy and weight loss, adrenal and pituitary disease from diagnostic testing to targeted oncology, and the long shadow of dysglycaemia across pregnancy, liver disease and rare growth disorders. Let's dive in.

We begin with semaglutide, and the question of how far its benefits extend beyond glucose and weight. In The Lancet Diabetes and Endocrinology, a prespecified pooled participant-level analysis of the SELECT, FLOW and SOUL trials brought together nearly 31,000 participants followed for roughly three to four years, spanning people with chronic kidney disease, people with atherosclerotic cardiovascular disease, and people with and without type 2 diabetes, and using both injected and oral semaglutide [1]. The primary composite of a persistent halving of estimated glomerular filtration rate, kidney failure, kidney-related death or cardiovascular death occurred in 973 semaglutide-treated participants versus 1,134 on placebo, a relative risk reduction of about 16 percent. The narrower kidney-only composite, stripping out cardiovascular death, fell by roughly 20 percent. Safety was in line with the wider GLP-1 class, and serious adverse events were numerically lower on semaglutide. The authors' interpretation is worth sitting with: benefit appeared consistent across the cardio-kidney-metabolic spectrum regardless of baseline characteristics, which argues that kidney protection is not simply a downstream consequence of better glycaemia or weight loss. Practically, this strengthens the case for considering semaglutide as organ-protective therapy in patients with cardiovascular or kidney disease, not only as a glucose-lowering or weight-lowering drug. Alongside this, the same journal published STEP 12, a phase 3b trial of once-weekly semaglutide 2.4 milligrams in 242 adults across mainland China and Taiwan, recruited using locally defined body mass index thresholds as low as 24 [4]. Over 44 weeks, weight fell by about 12 percent with semaglutide versus just over 2 percent with placebo, a treatment difference of nearly 10 percentage points, and 80 percent of the semaglutide group lost at least 5 percent of body weight compared with 24 percent on placebo. Gastrointestinal side effects dominated, as expected. The clinical message is that efficacy in an East Asian population with lower body mass index thresholds mirrors what we have seen in Western STEP trials, supporting treatment decisions based on population-specific adiposity criteria rather than a universal cut-off of 30.

That leads naturally into a paper in Diabetes Care that reminds us weight loss achieved without pharmacotherapy carries decades-long dividends. The Da Qing Diabetes Prevention Outcome Study followed 540 Chinese adults with impaired glucose tolerance for 34 years, grouped by weight change over the initial 6-year lifestyle intervention [2]. Compared with those who lost no weight, those who lost at least 5 percent had roughly a 44 percent lower risk of cardiovascular death, a 29 percent lower risk of cardiovascular events, a halving of heart failure hospitalisation, and about a third lower all-cause mortality, after adjustment for age, sex and baseline weight. Median time to cardiovascular death was delayed by six and a half years. This is observational within a trial cohort, so causality is not settled, but the size of the signal makes an important point for the clinic: modest early weight loss in prediabetes is not a cosmetic endpoint, it is a mortality intervention, and the window matters.

Staying with dysglycaemia across the life course, Diabetes Care also published a large retrospective cohort from Kaiser Permanente Southern California covering more than 326,000 mothers and 442,000 pregnancies followed for a median of just over six years [7]. Gestational diabetes was associated with a nearly six-fold higher risk of subsequent diabetes, and recurrent gestational diabetes with a roughly ten-fold higher risk. Asian women had both the highest rates of gestational diabetes, around 20 percent, and the highest recurrence rate, over half, and the highest post-recurrence diabetes risk, close to twelve-fold. The actionable point is that a second episode of gestational diabetes should trigger a materially more intensive surveillance and prevention plan than a first, and that ethnicity-specific risk stratification belongs in postpartum follow-up. Complementing this, a pragmatic review in the Journal of Clinical Endocrinology and Metabolism tackles diabetes in cirrhosis, an increasingly common convergence as metabolic dysfunction-associated steatotic liver disease drives the cirrhosis burden [8]. The authors highlight that HbA1c is unreliable in advanced liver disease, favouring oral glucose tolerance testing and continuous glucose monitoring; metformin remains the backbone in compensated disease, GLP-1 receptor agonists and SGLT2 inhibitors are attractive where steatotic liver disease and cardio-renal comorbidity coexist, sulfonylureas and agents causing fluid retention should be avoided as hepatic reserve falls, and insulin with conservative, dynamically titrated dosing is the mainstay in decompensated disease. The overarching principle is hepatic safety over rigid glycaemic targets.

Turning to the adrenal gland, two papers address very different problems. The CHIRACIC trial in the European Journal of Endocrinology randomised 48 patients with unilateral adrenal incidentaloma and mild autonomous cortisol secretion to adrenalectomy or conservative management [3]. Having previously shown benefit for hypertension, the investigators here report that the metabolic and quality-of-life story is far weaker. There was no statistically significant improvement in anthropometric or metabolic parameters: 21 percent of surgical patients lost more than 5 percent of body weight versus 4 percent managed conservatively, with confidence intervals crossing zero; glycaemic status improved in 44 percent versus 33 percent, again non-significant; and quality-of-life change did not differ between groups. This is a small trial, but the honest reading is that surgery for mild autonomous cortisol secretion should not be sold to patients on the promise of weight loss, better glycaemia or improved wellbeing. Also in the Journal of Clinical Endocrinology and Metabolism, a multicentre Korean common data model study of 307 patients undergoing saline infusion testing for suspected primary aldosteronism derived a decision tree from screening variables alone [6]. A phenotype of plasma aldosterone above 25 nanograms per decilitre with suppressed renin predicted a 96 percent confirmatory test positivity rate, while in the intermediate aldosterone band, potassium at or below 3.9 further stratified risk, and low aldosterone predicted low positivity. Overall accuracy was 0.85, outperforming rigid conventional cut-offs. In keeping with the 2025 Endocrine Society probability-based approach, this supports omitting confirmatory testing in the highest-probability patients and moving them straight to subtyping.

Finally, three papers on rarer endocrine disease. A review in the Journal of Clinical Endocrinology and Metabolism covers belzutifan, the first-in-class hypoxia-inducible factor 2 alpha inhibitor, for advanced pheochromocytoma and paraganglioma [5]. In the LITESPARK-015 phase 2 trial, belzutifan achieved an 85 percent disease control rate and a 26 percent overall response rate, with improved blood pressure control and quality of life, and predictable mechanism-based anaemia as the main toxicity. It is now the first oral and second approved therapy for metastatic disease, though molecular predictors of response remain undefined. In the same journal, a Swedish nationwide matched cohort compared 348 patients with acromegaly-associated diabetes with nearly 3,500 matched patients with type 2 diabetes [9]. Baseline cardiovascular disease was substantially more common in the acromegaly group, 61 versus 43 percent, and incident cardiovascular morbidity was about 55 percent higher, driven by venous thromboembolism, particularly pulmonary embolism, and arrhythmia. Overall and cardiovascular mortality, however, were not significantly increased. So despite the lean phenotype, these patients warrant vigilant cardiovascular and thromboembolic surveillance. And a cohort of 71 individuals with Temple syndrome from United Kingdom and Dutch centres defines the endocrine phenotype of this imprinting disorder [10]: most born small for gestational age, early feeding difficulties in 87 percent, obesity in 47 percent, central precocious puberty in 62 percent, dyslipidaemia in 38 percent, and confirmed growth hormone deficiency in 27 percent despite normal insulin-like growth factor 1 in all. Short stature improved with age, more so with growth hormone therapy. Only 56 percent met three or more Netchine-Harbison criteria, hence the proposed Temple-specific score to prompt earlier testing.

If you only have time for one paper this week, make it the pooled kidney analysis of SELECT, FLOW and SOUL in The Lancet Diabetes and Endocrinology [1]. It is the broadest evidence yet that semaglutide's kidney protection extends across the cardio-kidney-metabolic spectrum, including people without diabetes, and it will shape how you frame these drugs to patients and to nephrology colleagues.

Here are the key takeaways from this week in Endocrinology. Semaglutide reduced major kidney and cardiovascular-death outcomes by around 16 percent across nearly 31,000 pooled trial participants, with benefit apparently independent of glycaemic or weight effects. Semaglutide 2.4 milligrams produced 12 percent weight loss in Chinese adults recruited at locally defined body mass index thresholds, supporting population-specific treatment criteria. Early weight loss of at least 5 percent in prediabetes was linked to lower cardiovascular and all-cause mortality more than three decades later. Recurrent gestational diabetes carried a roughly ten-fold future diabetes risk, highest in Asian women, so escalate postpartum surveillance after a second episode. Adrenalectomy for mild autonomous cortisol secretion did not significantly improve weight, metabolic parameters or quality of life, so counsel patients accordingly. And a simple screening-stage decision tree may let you skip saline infusion testing in patients with markedly elevated aldosterone and suppressed renin.

That's your roundup for This Week in Endocrinology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.